...Vedat Uygun; Gülsün Karasu; Koray Yalçın; Seda Öztürkmen; Hayriye Daloğlu; Safiye Suna Çelen; Volkan Hazar; Akif Yeşilipek Background: The use of unmanipulated haploidentical hematopoietic stem cell transplantations (haplo-HSCT) with post-transplant cyclophosphamide (PTCY) in children has emerged...

...) may benefit from salvage chemoimmunotherapy (CIT). To explore further the use of CIT in the pre-novel agent era, ECOG-ACRIN undertook a phase 2 trial (E2903) for R/R CLL utilizing pentostatin, cyclophosphamide, and rituximab (PCR) followed by a consolidation course of alemtuzumab. This trial enrolled...

...; Junichi Mukae; Koh Yamamoto; Ikuyo Tsutsumi; Takuya Komeno; Chikashi Yoshida; Masahide Yamamoto; Hiroshi Kojima; on behalf of the Ochanomizu Hematology Study Group We assessed the efficacy and safety of weekly cyclophosphamide-bortezomib-dexamethasone (CBD) induction prior to autologous stem cell...

...K.N. Chin; G. Hudson A quantitative study of peritoneal cell populations has been carried out in mice at intervals of 6 h to 30 days after a single sublethal dose of cyclophosphamide. There was a severe depletion in the number of lymphoid cells, which was first detected at 12 h and reached...

...K. Hein; U. Kühner By means of cytochemistry lactate dehydrogenase (LDH), alkaline and acid phosphatase (AP, SP) were identified in megakaryocytes of the rat. Even the smallest dosage of cyclophosphamide caused a decrease of LDH and AP activity, while the activity of SP increased. Simultaneously...

...A.M. Marmont A 7-year-old male child with congenital hypoplastic anaemia (Diamond-Blackfan), having originally responded to corticosteroids, but having subsequently become refractory and erythroblastopenic since 4 years, was treated with a combination of cyclophosphamide (CY; 2.1 g...

...G.R. Standen; N.M. Blackett The erythroid and granulocytic repopulating ability of rat bone marrow has been measured after daily administration of three alkylating agents: dimethylmyleran, busulphan and cyclophosphamide. Three different patterns of response were observed. The results emphasize...

...) and combination therapy of prednisolone and cyclophosphamide. 23 04 1981 20 08 1981 26 2 2009 Acta haemat. 68: 58-62 (1982) Spontaneously Acquired Factor VIII Inhibitor in a 7-Year-Old Girl Koji Nakashima, Taeko Miyahara, Shinya Fujii, Kohei Kaku, Noboru Maisumoto, Toshio Kaneko Third...

...Vincent S. Gallicchio Studies are described that demonstrate the ability of lithium (Li) to enhance total peripheral blood neutrophil, platelet and stem cell (CFU-S, CFU-MIX, CFU-GM and CFU-MEG) populations from mice administered cyclophosphamide (CTX). Mice were preinjected on each of 3...

... leukemia. The 7q-, del(7)(q22q34), was seen in otherwise karyotypically normal cells. Cyclophosphamide was administered for 5 months during the maintenance therapy. Our observations indicate that unrelated karyotypes, besides karyotypic evolution, may be implicated in tumor cell heterogeneity and may...

...France Laurencet; Pierluigi Ballabeni; Beatrice Rufener; Urs Hess; Thomas Cerny; Martin Fey; Jean-Marc Luthi; Catherine Plancherel; Gilbert B. Zulian A multicenter trial was performed to confirm the therapeutic efficacy and the toxicity profile of the combination of cladribine, cyclophosphamide...

... chemotherapies in patients with multiple myeloma (MM). Although the granulocyte colony-stimulating factor (G-CSF), following chemotherapy or not, is considered the standard growth factor for mobilizing PBSC, the optimal chemotherapeutic regimen still remains to be defined. Cyclophosphamide (CTX) is an effective...

...O. Pšenák; L. Šefc; V. Sýkora; K.T. Chang; E. Nečas The goal of the study was to investigate changes in expression of selected growth factors tentatively involved in regeneration of haematopoietic tissues (bone marrow and spleen) following cyclophosphamide (CY) damage in the mouse. The bone marrow...

...A. Nagler; A. Ackerstein; M. Ben-Shahar; R. Or; E. Naparstek; R. Ben-Yosef; S. Slavin The combination of a cyclophosphamide (CTX)-based chemotherapy regimen and interleukin-2 (IL-2) has been shown to provide synergistic effects against malignancy in animal models. We therefore conducted a phase I...